Restarting Evenity (Romosozumab) After Acute Illness

Why the 12-Month Course Structure Matters for Restart Decisions

Romosozumab is not an ongoing maintenance drug. The FDA approved it as a 12-consecutive-month anabolic course, after which bone-formation markers return toward baseline and the agent must be followed by antiresorptive therapy to retain gains [1]. That fixed structure creates a clinical dilemma when an acute illness forces a missed dose or a multi-month gap: physicians must weigh whether the remaining months of the course are still worth completing, or whether the interrupted course has already compromised bone-density outcomes.

How the Anabolic Window Works

The bone-formation effect of romosozumab is front-loaded. In the FRAME trial (N=7,180), the largest increase in lumbar spine BMD occurred in the first six months of therapy [2]. Doses missed early in the course carry a higher cost to net bone gain than doses missed near month 11 or 12. A patient who receives only four of twelve doses because of a prolonged hospitalization may not achieve the BMD gains seen in trial participants who completed all twelve injections.

What "Acute Illness" Encompasses Clinically

For restart purposes, relevant acute illnesses include but are not limited to:

• Acute coronary syndrome, stroke, or TIA (trigger the boxed-warning contraindication)
• Serious infections requiring hospitalization (sepsis, pneumonia, osteomyelitis)
• Major surgery with prolonged immobilization
• Acute kidney injury that alters calcium-phosphate homeostasis
• Hypocalcemia or hyperparathyroidism flare

Each category carries a different restart timeline and a different risk profile.

The Cardiovascular Contraindication: The Most Consequential Restart Barrier

Romosozumab carries an FDA Boxed Warning stating that it is contraindicated in patients who have experienced a myocardial infarction or stroke within the preceding 12 months [1]. This restriction derives directly from the ARCH trial, where cardiovascular serious adverse events occurred in 2.5% of the romosozumab group versus 1.9% in the alendronate group during the first 12 months (P<0.05) [3].

Applying the 12-Month CV Window After an Acute Event

If a patient on romosozumab suffers a MI or ischemic stroke, the next romosozumab dose must not be given until at least 12 months after that event, per label language [1]. In practice, this means:

1. Discontinue romosozumab immediately on diagnosis of MI or stroke.
2. Begin guideline-directed antiresorptive therapy (typically oral bisphosphonate) to prevent rapid bone loss during the interruption.
3. Reassess cardiovascular status at the 12-month mark in collaboration with cardiology or neurology.
4. Restart romosozumab only if the patient is event-free, has no unstable coronary disease, and the benefit-risk balance favors completion of the remaining anabolic course.

The American Society for Bone and Mineral Research (ASBMR) 2022 clinical guidance states: "Clinicians should carefully evaluate the cardiovascular risk profile of each patient before initiating or reinitiating romosozumab, particularly in those with prior atherosclerotic events." [4]

When the CV Event Occurs Near Course Completion

A patient who suffers a MI at month 10 of a 12-month course has already received the majority of the anabolic benefit. Restarting for the remaining two doses after a 12-month cardiac-safe interval may not be cost-effective or necessary. In that scenario, transitioning directly to denosumab or alendronate is a reasonable alternative, and the decision should be documented in a shared clinical note signed by both the prescribing endocrinologist and a cardiologist.

Non-Cardiovascular Acute Illness: Restart Criteria and Timing

For illnesses that do not trigger the CV contraindication, no fixed FDA-mandated washout period applies. The decision to restart rests on three criteria assessed at each potential dose date.

Criterion 1: Serum Calcium Normalization

Romosozumab can worsen pre-existing hypocalcemia because anabolic bone formation consumes calcium rapidly. Before restarting after any acute illness, a serum calcium level must be documented as within normal limits [1]. In patients with acute kidney injury or those who have been on loop diuretics during their hospitalization, calcium may remain suppressed for weeks after discharge.

A 2019 analysis in the Journal of Bone and Mineral Research noted that pre-existing hypocalcemia was the most common metabolic contraindication requiring delay of romosozumab initiation in a real-world cohort of 312 patients [5].

Criterion 2: Resolution of the Acute Illness to Clinical Stability

"Clinical stability" is not defined by a specific lab value but by the treating physician's judgment that the patient can safely resume an injectable anabolic agent. Practically, this means:

• Afebrile for at least 48 to 72 hours after antibiotic completion in serious infections
• Adequate oral intake and no ongoing GI losses that would compromise calcium absorption
• Renal function at or near the patient's personal baseline (romosozumab has not been studied in patients with creatinine clearance <30 mL/min)

Criterion 3: Re-Evaluation of the Overall Treatment Goal

An acute illness sometimes changes the patient's prognosis, functional status, or life expectancy in ways that alter the benefit-risk calculus for continuing a 12-month anabolic course. A new cancer diagnosis, a major disabling stroke, or progression to end-stage renal disease may shift the priority away from long-term fracture prevention. The prescribing clinician should document an explicit re-evaluation of treatment goals at restart.

Practical Restart Protocol: A Step-by-Step Clinical Framework

The following framework synthesizes FDA label requirements [1], ARCH trial safety data [3], and published endocrinology practice guidance [4] into an actionable sequence.

Step 1: Classify the Reason for the Interruption

| Interruption Type | Restart Allowed? | Minimum Wait | |---|---|---| | MI or ischemic stroke | Yes, conditionally | 12 months from event | | TIA (no infarct) | Clinical judgment | 3 to 6 months, cardiology clearance | | Serious infection (hospitalized) | Yes | Resolution + clinical stability | | Elective surgery with immobility | Yes | Full weight-bearing restored | | Hypocalcemia | Yes | Serum Ca normalized | | AKI | Yes | CrCl returned to baseline | | New cancer diagnosis | Case-by-case | Oncology and endocrinology co-decision |

Step 2: Order Pre-Restart Labs

Minimum lab panel before the delayed dose:

• Serum total calcium and albumin (or ionized calcium)
• Serum phosphorus
• 25-hydroxyvitamin D
• Basic metabolic panel (serum creatinine, eGFR)
• PTH if hypocalcemia suspected

Step 3: Reassess Cumulative Dose Count and Remaining Benefit

If the patient has received six or more doses, substantial BMD gain has likely occurred based on FRAME trial kinetics [2]. Completing the remaining doses preserves anabolic momentum. If fewer than four doses were received, the treating team should weigh whether the net benefit of the remaining doses justifies restarting, given that no published trial data exist for partial-course re-initiation after a major illness gap.

Step 4: Document Shared Decision-Making

Given the boxed cardiovascular warning and the absence of head-to-head data comparing interrupted versus uninterrupted romosozumab courses, a documented shared decision-making conversation is both clinically appropriate and medicolegally protective. The note should include the patient's understanding of the CV risk, the expected residual BMD benefit, and the plan for antiresorptive follow-on therapy after the course ends.

Step 5: Schedule the Dose and Resume Monthly Cadence

Once cleared, administer the next 210 mg dose (two simultaneous 105 mg SC injections) and reset the monthly calendar from that date. Do not attempt to "catch up" by shortening the interval between doses. No published safety data support intervals shorter than 28 days.

Bone Loss During the Interruption: What to Expect and How to Mitigate It

Missed romosozumab doses do not simply pause BMD gains. During any gap in therapy, the anabolic drive disappears immediately because romosozumab's half-life is approximately 6.4 days [1]. Residual sclerostin inhibition dissipates within two to three weeks. Without a bridging antiresorptive, bone resorption markers can rebound within 30 to 60 days of the last dose.

Bridging with Antiresorptive Therapy During a Long Gap

For interruptions expected to last more than two to three months, many endocrinologists bridge with an oral bisphosphonate (typically alendronate 70 mg weekly) to limit resorptive bone loss. This bridging strategy is off-label for this specific context but is consistent with the general principle that bone gains from anabolic therapy are preserved by immediate antiresorptive follow-on, as demonstrated in the ARCH trial's sequential arm [3].

Denosumab is generally not used as a bridge because its own discontinuation causes a rapid rebound in bone resorption that can be more difficult to manage than the original fracture risk, per a 2019 Lancet Diabetes and Endocrinology analysis [6].

Calcium and Vitamin D During the Gap

Calcium 500 mg and vitamin D 400 to 800 IU daily should continue uninterrupted throughout any therapy gap. A 25-hydroxyvitamin D level <20 ng/mL at restart requires repletion before the next romosozumab injection to minimize hypocalcemia risk.

After Completing the Interrupted Course: Follow-On Therapy Is Non-Negotiable

Whether the 12-month course was interrupted or uninterrupted, antiresorptive therapy must begin promptly after the last romosozumab dose. BMD gains are partially or fully lost without follow-on treatment. The ARCH trial demonstrated that patients transitioned to alendronate after romosozumab maintained significantly better hip BMD at 24 months than patients who received alendronate alone from the start [3].

The Endocrine Society's 2020 Clinical Practice Guideline for osteoporosis pharmacotherapy states: "After completing a course of anabolic therapy, antiresorptive treatment should be initiated promptly to prevent the loss of bone density gains." [7]

Denosumab (60 mg SC every 6 months) is an alternative follow-on agent for patients who cannot tolerate oral bisphosphonates. If denosumab is chosen, it must be continued without interruption because discontinuation causes a rapid rebound fracture risk that has been associated with vertebral crush fractures in multiple published case series [6].

Special Populations: Modified Restart Considerations

Patients Over Age 75

Older patients are disproportionately affected by acute illness and are also at the highest absolute fracture risk. The benefit of completing an interrupted romosozumab course may be greater in this group because their baseline 10-year fracture probability (FRAX score) is higher, meaning each unit of BMD gain translates to a larger absolute risk reduction. CV comorbidity is also more prevalent, making individualized cardiology input more important.

Male Patients with Osteoporosis

Romosozumab received FDA approval for men at high fracture risk in 2022 based on the BRIDGE trial (N=245), which showed a 12.1% increase in lumbar spine BMD versus placebo at 12 months [8]. The BRIDGE trial did not specifically examine post-illness restart, but the same physiological principles apply. The CV boxed warning applies equally to men.

Patients with Glucocorticoid-Induced Osteoporosis

Glucocorticoid-induced osteoporosis (GIOP) is a frequent comorbidity in patients who suffer acute inflammatory illnesses (lupus flare, severe asthma, inflammatory bowel disease exacerbation). An acute illness requiring high-dose glucocorticoid therapy accelerates bone loss precisely when romosozumab is interrupted. This double hit makes rapid restart after clinical stabilization especially important in GIOP patients. A 2020 study in the Journal of Bone and Mineral Research showed that glucocorticoid use of 7.5 mg prednisone equivalent daily for 3 months reduced lumbar spine BMD by approximately 3% [9], a magnitude that partially offsets romosozumab's anabolic gains.

Monitoring After Restart

Once therapy resumes, no additional monitoring beyond routine care is required unless the acute illness altered the patient's metabolic baseline. Specific post-restart monitoring triggers include:

• Repeat serum calcium at 2 to 4 weeks after the delayed dose if the patient had documented hypocalcemia during the illness
• Repeat eGFR at 4 weeks if AKI occurred during the hospitalization
• Repeat DXA at 12 months after completing the full course (standard of care regardless of interruption) to document BMD response

The FDA label does not require routine cardiac monitoring during romosozumab therapy beyond the initial CV risk assessment, but clinical judgment should guide frequency of cardiovascular review in high-risk patients [1].